Literature DB >> 6682017

A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).

R Harrison, C A McAuliffe, A Zaki, J Baer, H Sharma, A Smith, H Jackson, B W Fox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6682017     DOI： 10.1007/bf00446216

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  14 in total

1.  Analysis for platinum in biological material by flameless atomic absorption spectrometry.

Authors:  M F Pera; H C Harder
Journal:  Clin Chem       Date:  1977-07       Impact factor: 8.327

2.  Metabolism of platinum ( 14 C)ethylenediamine dichloride in the rat.

Authors:  D M Taylor; J D Jones; A B Robins
Journal:  Biochem Pharmacol       Date:  1973-04-01       Impact factor: 5.858

3.  Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man.

Authors:  H S Smith; D M Taylor
Journal:  J Nucl Med       Date:  1974-05       Impact factor: 10.057

4.  The antitumor agent cis-Pt(NH 3 ) 2 Cl 2 : distribution studies and dose calculations for 193m Pt and 195m Pt.

Authors:  R C Lange; R P Spencer; H C Harder
Journal:  J Nucl Med       Date:  1973-04       Impact factor: 10.057

5.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man.

Authors:  T F Patton; K J Himmelstein; R Belt; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1978-09

Review 6.  Cis-diamminedichloroplatinum (II). A new anticancer drug.

Authors:  M Rozencweig; D D von Hoff; M Slavik; F M Muggia
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

7.  Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum(II).

Authors:  S J Bannister; Y Chang; L A Sternson; A J Repta
Journal:  Clin Chem       Date:  1978-06       Impact factor: 8.327

8.  Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).

Authors:  P A DeSimone; R S Yancey; J J Coupal; J D Butts; J D Hoeschel
Journal:  Cancer Treat Rep       Date:  1979-06

9.  Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model.

Authors:  E Cvitkovic; J Spaulding; V Bethune; J Martin; W F Whitmore
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

10.  Criteria for the selection of second-generation platinum compounds.

Authors:  R Shepherd; H Kusnierczyk; M Jones; K R Harrap
Journal:  Br J Cancer       Date:  1980-11       Impact factor: 7.640
View more
  5 in total

1.  An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin.

Authors:  C Ewen; A Perera; J H Hendry; C A McAuliffe; H Sharma; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin.

Authors:  B Hecquet; P Vennin; C Fournier; J L Lefebvre; A Caty; J Bonneterre; L Adenis; A Demaille
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.

Authors:  F F Farris; F G King; R L Dedrick; C L Litterst
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

4.  The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin.

Authors:  S E Dible; Z H Siddik; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.

Authors:  S E Owens; N Thatcher; H Sharma; N Adam; R Harrison; A Smith; A Zaki; J C Baer; C A McAuliffe; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.